Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $97
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $89 to $97.
Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $89 to $97.